Targeted Disease(s):
Non-Cystic Fibrosis Bronchiectasis

Purpose of Study:

This is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, 52 week Phase III study to test the hypothesis that benralizumab will reduce exacerbation rates compared with placebo on top of standard-of-care therapy in adult patients with non-cystic fibrosis bronchiectasis with eosinophilic inflammation (NCFB+EI).All patients who complete the 52-week double-blind treatment period on investigational product (IP) may be eligible to continue into an open-label extension (OLE), during which all patients will receive benralizumab.The OLE treatment period is intended to allow patients at least one year of treatment with open label benralizumab.

Study Dates:
July 21, 2021 - June 10, 2021

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
AstraZeneca

ClinicalTrails.gov Identifier:
NCT05006573

Contacts:
Name: AstraZeneca Clinical Study Information Center
Phone: 1-877-240-9479
Email: [email protected]

Sponsor:
AstraZeneca

Trial URL:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=26429

Register for Trial
Freedom From Smoking Clinic
, | Sep 29, 2021
COPD Educator Course
, | Oct 20, 2021